Generic placeholder image

Current HIV Research

Editor-in-Chief

ISSN (Print): 1570-162X
ISSN (Online): 1873-4251

Research Article

Pidotimod and Immunological Activation in Individuals Infected with HIV

Author(s): Claudio Ucciferri, Katia Falasca*, Marcella Reale, Manuela Tamburro, Antonio Auricchio, Francesca Vignale and Jacopo Vecchiet

Volume 19 , Issue 3 , 2021

Published on: 11 January, 2021

Page: [260 - 268] Pages: 9

DOI: 10.2174/1570162X18666210111102046

open access plus

Abstract

Background: The improvements in HIV infection therapy and the large availability of antiretroviral drugs have led to an increased survival among HIV infected people, and simultaneously to a raised morbidity and mortality due to not-AIDS-related events in this group compared to the general population. An increased systemic inflammation and a persistent immune activation play a pivotal role in determining high rates of non-AIDS comorbidities. In the last years, many natural or synthetic immunomodulatory molecules acting by different mechanisms have been conceived. Pidotimod is a synthetic dipeptide molecule showing immunomodulatory properties. The aim of this pilot study was to evaluate the effects of Pidotimod supplementation on residual inflammation in HIV infected population.

Methods: Forty HIV positive individuals under cART were enrolled: 30 were treated with Pidotimod supplementation (study group) and 10 served as control group (without Pidotimod supplementation). For all participants, Cystatin C, PCR, ESR, microalbuminuria, TNF-α, INF-γ, IL-4, IL-10, IL1β, IL-18 and IL-2 were measured at enrolment (T0), 4 weeks after of Pidotimod supplementation (T1), and 4 weeks after completing supplementation (T2).

Results: In HIV positive participants treated with Pidotimod, the evaluation of cytokine levels showed that IL-10, IFN gamma, and IL-4 were significantly higher at enrolment compared to the control group. The increase under Pidotimod treatment persisted after supplementation suspension, while the pro-inflammatory cytokines levels were reduced. Salivary IgA also increased during 4 weeks of supplementation and persisted at 4 weeks after completing supplementation. On the other hand, the Cystatin C and microalbuminuria levels decreased over time, at a greater extent the Cystatin C serum levels.

Conclusion: The study findings showed that the HIV population receiving Pidotimod achieved a rebalancing of pro-inflammatory and anti-inflammatory cytokines as well as a significant reduction in cystatin C levels. The treatment further allowed for an increase in salivary IgA levels at all the analyzed times, as a secondary event to a remodulation of the immunological status obtained with pidotimod. This approach could represent a new way to design new intervention strategies aimed at improving the persistent immune activation status in the virologically suppressed HIV population.

Keywords: Supplementation, AIDS, cytokines, immunostimulatory, inflammation, immunological rebalancing.

Graphical Abstract
[1]
Samji H, Cescon A, Hogg RS, et al. North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) of IeDEA. Closing the gap: increases in life expectancy among treated HIV-positive individuals in the United States and Canada. PLoS One 2013; 8(12) e81355
[http://dx.doi.org/10.1371/journal.pone.0081355] [PMID: 24367482]
[2]
Lewden C, Bouteloup V, De Wit S, et al. Collaboration of Observational HIV Epidemiological Research Europe (COHERE) in EuroCoord. All-cause mortality in treated HIV-infected adults with CD4 ≥500/mm3 compared with the general population: evidence from a large European observational cohort collaboration. Int J Epidemiol 2012; 41(2): 433-45.
[http://dx.doi.org/10.1093/ije/dyr164] [PMID: 22493325]
[3]
Vargas-Pacherrez D, Cotrim HP, Pires L, et al. Metabolic Syndrome in HIV-patients in Antiretroviral Therapy. Curr HIV Res 2020; 18(6): 388-95.
[http://dx.doi.org/10.2174/1570162X18666200609115615] [PMID: 32516101]
[4]
Falasca K, Di Nicola M, Porfilio I, et al. Predictive factors and prevalence of microalbuminuria in HIV-infected patients: a cross-sectional analysis. BMC Nephrol 2017; 18(1): 255.
[http://dx.doi.org/10.1186/s12882-017-0672-9] [PMID: 28754089]
[5]
Hileman CO, Funderburg NT. Inflammation, Immune Activation, and Antiretroviral Therapy in HIV. Curr HIV/AIDS Rep 2017; 14(3): 93-100.
[http://dx.doi.org/10.1007/s11904-017-0356-x] [PMID: 28434169]
[6]
Heaton RK, Clifford DB, Franklin DR Jr, et al. CHARTER Group. HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study. Neurology 2010; 75(23): 2087-96.
[http://dx.doi.org/10.1212/WNL.0b013e318200d727] [PMID: 21135382]
[7]
Falasca K, Ucciferri C, Mancino P, et al. Cystatin C, adipokines and cardiovascular risk in HIV infected patients. Curr HIV Res 2010; 8(5): 405-10.
[http://dx.doi.org/10.2174/157016210791330365] [PMID: 20426756]
[8]
Falasca K, Reale M, Ucciferri C, et al. Cytokines, Hepatic Fibrosis, and Antiretroviral Therapy Role in Neurocognitive Disorders HIV Related. AIDS Res Hum Retroviruses 2017; 33(3): 246-53.
[http://dx.doi.org/10.1089/aid.2016.0138] [PMID: 27615271]
[9]
Ucciferri C, Falasca K, Vecchiet J. Hypertension in HIV: Management and Treatment. AIDS Rev 2017; 19(4): 198-211.
[PMID: 28534890]
[10]
Ucciferri C, Falasca K, Vignale F, Di Nicola M, Vecchiet J. Long term effect of telmisartan in HIV-positive male patients with high blood pressure. Braz J Infect Dis 2015; 19(6): 668-9.
[http://dx.doi.org/10.1016/j.bjid.2015.08.012] [PMID: 26477384]
[11]
Lifson AR, Lando HA. Smoking and HIV: prevalence, health risks, and cessation strategies. Curr HIV/AIDS Rep 2012; 9(3): 223-30.
[http://dx.doi.org/10.1007/s11904-012-0121-0] [PMID: 22618079]
[12]
Kotler DP. HIV and antiretroviral therapy: lipid abnormalities and associated cardiovascular risk in HIV-infected patients. J Acquir Immune Defic Syndr 2008; 49(Suppl. 2): S79-85.
[http://dx.doi.org/10.1097/QAI.0b013e318186519c] [PMID: 18725816]
[13]
Grand M, Bia D, Diaz A. Cardiovascular Risk Assessment in People Living With HIV: A Systematic Review and Meta-Analysis of Real-Life Data. Curr HIV Res 2020; 18(1): 5-18.
[http://dx.doi.org/10.2174/1570162X17666191212091618] [PMID: 31830884]
[14]
Sabin CA, Worm SW, Weber R, et al. D:A:D Study Group. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. Lancet 2008; 371(9622): 1417-26.
[http://dx.doi.org/10.1016/S0140-6736(08)60423-7] [PMID: 18387667]
[15]
Obel N, Farkas DK, Kronborg G, et al. Abacavir and risk of myocardial infarction in HIV-infected patients on highly active antiretroviral therapy: a population-based nationwide cohort study. HIV Med 2010; 11(2): 130-6.
[http://dx.doi.org/10.1111/j.1468-1293.2009.00751.x] [PMID: 19682101]
[16]
Ucciferri C, Falasca K, Vignale F, Di Nicola M, Vecchiet J. Long term effect of switching to darunavir/ritonavir in HIV infected patients previously on protease inhibitor therapy. Braz J Infect Dis 2016; 20(4): 401-2.
[http://dx.doi.org/10.1016/j.bjid.2016.02.002] [PMID: 26971833]
[17]
Ucciferri C, Falasca K, Vignale F, Di Nicola M, Pizzigallo E, Vecchiet J. Improved metabolic profile after switch to darunavir/ritonavir in HIV positive patients previously on protease inhibitor therapy. J Med Virol 2013; 85(5): 755-9.
[http://dx.doi.org/10.1002/jmv.23543] [PMID: 23508901]
[18]
Kaplan RC, Tien PC, Lazar J. Antiretroviral drugs and the risk of myocardial infarction. N Engl J Med 2007; 357(7): 715.
[http://dx.doi.org/10.1056/NEJMc071419] [PMID: 17699825]
[19]
Falasca K, Reale M, Di Nicola M, et al. Circulating CD40 ligand, Dickkopf-1 and P-selectin in HIV-infected patients. HIV Med 2019; 20(10): 681-90.
[http://dx.doi.org/10.1111/hiv.12789] [PMID: 31424619]
[20]
Teofili L, Iachininoto MG, Capodimonti S, et al. Endothelial progenitor cell trafficking in human immunodeficiency virus-infected persons. AIDS 2010; 24(16): 2443-50.
[http://dx.doi.org/10.1097/QAD.0b013e32833ef79d] [PMID: 20827169]
[21]
Bahrami H, Budoff M, Haberlen SA, et al. Inflammatory Markers Associated With Subclinical Coronary Artery Disease: The Multicenter AIDS Cohort Study. J Am Heart Assoc 2016; 5(6) e003371
[http://dx.doi.org/10.1161/JAHA.116.003371] [PMID: 27353609]
[22]
Darcis G, Berkhout B, Pasternak AO. Differences in HIV Markers between Infected Individuals Treated with Different ART Regimens: Implications for the Persistence of Viral Reservoirs. Viruses 2020; 12(5) 489
[http://dx.doi.org/10.3390/v12050489] [PMID: 32349381]
[23]
Vecchiet J, Iachininoto MG, Capodimonti S, et al. Effect of antiviral therapy on pro-angiogenic hematopoietic and endothelial progenitor cells in HIV-infected people. Thromb Res 2013; 131(3): 238-43.
[http://dx.doi.org/10.1016/j.thromres.2012.12.007] [PMID: 23290306]
[24]
Thomas LV, Suzuki K, Zhao J. Probiotics: a proactive approach to health. A symposium report. Br J Nutr 2015; 114(Suppl. 1): S1-S15.
[http://dx.doi.org/10.1017/S0007114515004043] [PMID: 26548336]
[25]
Falasca K, Vecchiet J, Ucciferri C, Di Nicola M, D’Angelo C, Reale M. Effect of Probiotic Supplement on Cytokine Levels in HIV-Infected Individuals: A Preliminary Study. Nutrients 2015; 7(10): 8335-47.
[http://dx.doi.org/10.3390/nu7105396] [PMID: 26426044]
[26]
Munkombwe D, Muungo TL, Michelo C, Kelly P, Chirwa S, Filteau S. Lipid-based nutrient supplements containing vitamins and minerals attenuate renal electrolyte loss in HIV/AIDS patients starting antiretroviral therapy: A randomized controlled trial in Zambia. Clin Nutr ESPEN 2016; 13: e8-e14.
[http://dx.doi.org/10.1016/j.clnesp.2016.03.002] [PMID: 28531643]
[27]
Haile ZT, Sarfo B, Bonney EY, Mensah EA, Deletsu S. Association between Antiretroviral Treatment and Markers of Systemic Inflammation among HIV Patients in Ghana. Curr HIV Res 2020; 18(6): 466-74.
[http://dx.doi.org/10.2174/1570162X18666200817111152] [PMID: 32807057]
[28]
Zuccotti GV, Mameli C. Pidotimod: the past and the present. Ital J Pediatr 2013; 39: 75.
[http://dx.doi.org/10.1186/1824-7288-39-75] [PMID: 24314100]
[29]
Puggioni F, Alves-Correia M, Mohamed MF, et al. Immunostimulants in respiratory diseases: focus on Pidotimod. Multidiscip Respir Med 2019; 14: 31.
[http://dx.doi.org/10.1186/s40248-019-0195-2] [PMID: 31700623]
[30]
D’Amato M, Paris D, Molino A, et al. The Immune-Modulator Pidotimod Affects the Metabolic Profile of Exhaled Breath Condensate in Bronchiectatic Patients: A Metabolomics Pilot Study. Front Pharmacol 2019; 10: 1115.
[http://dx.doi.org/10.3389/fphar.2019.01115] [PMID: 31632269]
[31]
Migliorati G, D’Adamio L, Coppi G, Nicoletti I, Riccardi C. Pidotimod stimulates natural killer cell activity and inhibits thymocyte cell death. Immunopharmacol Immunotoxicol 1992; 14(4): 737-48.
[http://dx.doi.org/10.3109/08923979209009231] [PMID: 1294620]
[32]
Giagulli C, Noerder M, Avolio M, et al. Pidotimod promotes functional maturation of dendritic cells and displays adjuvant properties at the nasal mucosa level. Int Immunopharmacol 2009; 9(12): 1366-73.
[http://dx.doi.org/10.1016/j.intimp.2009.08.010] [PMID: 19712757]
[33]
Trabattoni D, Clerici M, Centanni S, Mantero M, Garziano M, Blasi F. Immunomodulatory effects of pidotimod in adults with community-acquired pneumonia undergoing standard antibiotic therapy. Pulm Pharmacol Ther 2017; 44: 24-9.
[http://dx.doi.org/10.1016/j.pupt.2017.03.005] [PMID: 28302543]
[34]
Manti S, Parisi GF, Papale M, Leonardi S. Pidotimod in allergic diseases: the state of art. Minerva Pediatr 2020; 72(5): 358-63.
[http://dx.doi.org/10.23736/S0026-4946.20.05967-8]
[35]
Zhao N, Liu C, Zhu C, Dong X, Liu X. Pidotimod: a review of its pharmacological features and clinical effectiveness in respiratory tract infections. Expert Rev Anti Infect Ther 2019; 17(10): 803-18.
[http://dx.doi.org/10.1080/14787210.2019.1679118] [PMID: 31603361]
[36]
Esposito S, Garziano M, Rainone V, et al. Immunomodulatory activity of pidotimod administered with standard antibiotic therapy in children hospitalized for community-acquired pneumonia. J Transl Med 2015; 13: 288.
[http://dx.doi.org/10.1186/s12967-015-0649-z] [PMID: 26335787]
[37]
Ucciferri C, Barone M, Vecchiet J, Falasca K. Pidotimod in Paucisymptomatic SARS-CoV2 Infected Patients. Mediterr J Hematol Infect Dis 2020; 12(1) e2020048
[http://dx.doi.org/10.4084/mjhid.2020.048] [PMID: 32670526]
[38]
Psomas CK, Kinloch S. Highlights of the 17th European AIDS Clinical Society (EACS) Conference, 6-9 November 2019, Basel, Switzerland. J Virus Erad 2020; 6(1): 38-44.
[http://dx.doi.org/10.1016/S2055-6640(20)30010-8] [PMID: 32175091]
[39]
Ferrario BE, Garuti S, Braido F, Canonica GW. Pidotimod: the state of art. Clin Mol Allergy 2015; 13(1): 8.
[http://dx.doi.org/10.1186/s12948-015-0012-1] [PMID: 25999796]
[40]
Tang MLK, Hsiao KC, Ponsonby AL, et al. Probiotics and oral immunotherapy for peanut allergy - Authors’ reply. Lancet Child Adolesc Health 2017; 1(3): e1-2.
[http://dx.doi.org/10.1016/S2352-4642(17)30101-3] [PMID: 30169172]
[41]
Weinberger B. Vaccines for the elderly: current use and future challenges. Immun Ageing 2018; 15: 3.
[http://dx.doi.org/10.1186/s12979-017-0107-2] [PMID: 29387135]
[42]
Borghi MO, Minonzio F, Fain C, et al. [Effect of pidotimod on the function of the human immune system: In vitro and ex vivo study]. Drugs Exp Clin Res 1993; 19(Suppl.): 37-43.
[PMID: 8625781]
[43]
Kaplan-Lewis E, Aberg JA, Lee M. Aging with HIV in the ART era. Semin Diagn Pathol 2017; 34(4): 384-97.
[http://dx.doi.org/10.1053/j.semdp.2017.04.002] [PMID: 28552209]
[44]
Lu W, Mehraj V, Vyboh K, Cao W, Li T, Routy JP. CD4:CD8 ratio as a frontier marker for clinical outcome, immune dysfunction and viral reservoir size in virologically suppressed HIV-positive patients. J Int AIDS Soc 2015; 18: 20052.
[http://dx.doi.org/10.7448/IAS.18.1.20052] [PMID: 26130226]
[45]
Castilho JL, Turner M, Shepherd BE, et al. CD4/CD8 Ratio and CD4 Nadir Predict Mortality Following Noncommunicable Disease Diagnosis in Adults Living with HIV. AIDS Res Hum Retroviruses 2019; 35(10): 960-7.
[http://dx.doi.org/10.1089/aid.2019.0064] [PMID: 31407605]
[46]
Serrano-Villar S, Sainz T, Lee SA, et al. HIV-infected individuals with low CD4/CD8 ratio despite effective antiretroviral therapy exhibit altered T cell subsets, heightened CD8+ T cell activation, and increased risk of non-AIDS morbidity and mortality. PLoS Pathog 2014; 10(5) e1004078
[http://dx.doi.org/10.1371/journal.ppat.1004078] [PMID: 24831517]
[47]
Trickey A, May MT, Schommers P, et al. Antiretroviral Therapy Cohort Collaboration (ART-CC). CD4:CD8 Ratio and CD8 Count as Prognostic Markers for Mortality in Human Immunodeficiency Virus-Infected Patients on Antiretroviral Therapy: The Antiretroviral Therapy Cohort Collaboration (ART-CC). Clin Infect Dis 2017; 65(6): 959-66.
[http://dx.doi.org/10.1093/cid/cix466] [PMID: 28903507]
[48]
Serrano J, Román J, Herrera C, et al. Increasing mixed haematopoietic chimaerism after BMT with total depletion of CD4+ and partial depletion of CD8+ lymphocytes is associated with a higher incidence of relapse. Bone Marrow Transplant 1999; 23(5): 475-82.
[http://dx.doi.org/10.1038/sj.bmt.1701604] [PMID: 10100562]
[49]
Mussini C, Lorenzini P, Cozzi-Lepri A, et al. Icona Foundation Study Group. CD4/CD8 ratio normalisation and non-AIDS-related events in individuals with HIV who achieve viral load suppression with antiretroviral therapy: an observational cohort study. Lancet HIV 2015; 2(3): e98-e106.
[http://dx.doi.org/10.1016/S2352-3018(15)00006-5] [PMID: 26424550]
[50]
Cirioni O, Castelletti S, Ucciferri C, et al. Antiretroviral therapy management and rationalisation of available resources. Infez Med 2015; 23(4): 330-5.
[PMID: 26700083]
[51]
Wada NI, Jacobson LP, Margolick JB, et al. The effect of HAART-induced HIV suppression on circulating markers of inflammation and immune activation. AIDS 2015; 29(4): 463-71.
[http://dx.doi.org/10.1097/QAD.0000000000000545] [PMID: 25630041]
[52]
Rimaniol AC, Zylberberg H, Zavala F, Viard JP. Inflammatory cytokines and inhibitors in HIV infection: correlation between interleukin-1 receptor antagonist and weight loss. AIDS 1996; 10(12): 1349-56.
[http://dx.doi.org/10.1097/00002030-199610000-00006] [PMID: 8902063]
[53]
Gutierrez MDM, Mateo MG, Vidal F, Domingo P. Does choice of antiretroviral drugs matter for inflammation? Expert Rev Clin Pharmacol 2019; 12(5): 389-96.
[http://dx.doi.org/10.1080/17512433.2019.1605902] [PMID: 31017494]
[54]
Hocini H, Bonnabau H, Lacabaratz C, et al. HIV Controllers Have Low Inflammation Associated with a Strong HIV-Specific Immune Response in Blood. J Virol 2019; 93(10) e01690-18
[http://dx.doi.org/10.1128/JVI.01690-18] [PMID: 30814287]
[55]
Nelson B. As the HIV-positive population ages, new dangers loom: Researchers are exploring human immunodeficiency virus- mediated inflammation and immune dysregulation to better understand the higher risks of cancer, cardiovascular disease, and other conditions among individuals who carry the virus. Cancer Cytopathol 2019; 127(1): 5-6.
[http://dx.doi.org/10.1002/cncy.22097] [PMID: 30661307]
[56]
Winston A, Stöhr W, Antinori A, et al. NEAT 001/Agence Nationale de Recherche sur le SIDA (ANRS) 143 Study Group. Host and disease factors are associated with cognitive function in European HIV-infected adults prior to initiation of antiretroviral therapy. HIV Med 2016; 17(6): 471-8.
[http://dx.doi.org/10.1111/hiv.12344] [PMID: 26611175]
[57]
Auteri A, Pasqui AL, Bruni F, Saletti M, Di Renzo M, Bova G. Effect of Pidotimod, a new immunostimulating agent, on some aspects of immune response. In vitro study. Pharmacol Res 1992; 26(Suppl. 2): 196-7.
[http://dx.doi.org/10.1016/1043-6618(92)90662-U] [PMID: 1409308]
[58]
Caccuri F, Bugatti A, Corbellini S, et al. The Synthetic Dipeptide Pidotimod Shows a Chemokine-Like Activity through CXC Chemokine Receptor 3 (CXCR3). Int J Mol Sci 2019; 20(21) 5287
[http://dx.doi.org/10.3390/ijms20215287] [PMID: 31653015]
[59]
Annoni G, Arosio B, Santambrogio D, Cullurà D, Gagliano N, Uslenghi C. Gene expression for interleukin-2 and tumor necrosis factor-alpha in the spleen of old rats under physiological condition and during septic shock. Possible pharmacological modulation. Arzneimittelforschung 1994; 44(12A): 1433-6.
[PMID: 7531977]
[60]
Gourgiotis D, Papadopoulos NG, Bossios A, Zamanis P, Saxoni- Papageorgiou P. Immune modulator pidotimod decreases the in vitro expression of CD30 in peripheral blood mononuclear cells of atopic asthmatic and normal children. J Asthma 2004; 41(3): 285-7.
[http://dx.doi.org/10.1081/JAS-120026085] [PMID: 15260461]
[61]
Niu H, Wang R, Jia YT, Cai Y. Pidotimod, an immunostimulant in pediatric recurrent respiratory tract infections: A meta-analysis of randomized controlled trials. Int Immunopharmacol 2019; 67: 35-45.
[http://dx.doi.org/10.1016/j.intimp.2018.11.043] [PMID: 30530167]
[62]
Falasca K, Manigrasso MR, Racciatti D, et al. Associations between hypertriglyceridemia and serum ghrelin, adiponectin, and IL-18 levels in HIV-infected patients. Ann Clin Lab Sci 2006; 36(1): 59-66.
[PMID: 16501238]
[63]
Vecchiet J, Ucciferri C, Falasca K, Mancino P, Di Iorio A, De Caterina R. Antihypertensive and metabolic effects of telmisartan in hypertensive HIV-positive patients. Antivir Ther 2011; 16(5): 639-45.
[http://dx.doi.org/10.3851/IMP1809] [PMID: 21817185]
[64]
Javed F, Akram Z, Binshabaib MS, ALHarthi SS, Kellesarian SV, Vohra F. Is salivary IgA level a potential biomarker for immunosuppression in HIV-positive children? A systematic review and meta-analysis. Rev Med Virol 2017; 27(4)
[http://dx.doi.org/10.1002/rmv.1933] [PMID: 28573797]
[65]
Subramaniam P, Kumar K. Oral mucosal status and salivary IgA levels of HIV-infected children. J Oral Pathol Med 2013; 42(9): 705-10.
[http://dx.doi.org/10.1111/jop.12061] [PMID: 23551639]
[66]
Shlipak MG, Sarnak MJ, Katz R, et al. Cystatin C and the risk of death and cardiovascular events among elderly persons. N Engl J Med 2005; 352(20): 2049-60.
[http://dx.doi.org/10.1056/NEJMoa043161] [PMID: 15901858]
[67]
Hirata T, Arai Y, Yuasa S, et al. Associations of cardiovascular biomarkers and plasma albumin with exceptional survival to the highest ages. Nat Commun 2020; 11(1): 3820.
[http://dx.doi.org/10.1038/s41467-020-17636-0] [PMID: 32732919]
[68]
Choi A, Scherzer R, Bacchetti P, et al. Cystatin C, albuminuria, and 5-year all-cause mortality in HIV-infected persons. Am J Kidney Dis 2010; 56(5): 872-82.
[http://dx.doi.org/10.1053/j.ajkd.2010.05.019] [PMID: 20709438]
[69]
Chazot R, Botelho-Nevers E, Mariat C, et al. Cystatin C and urine albumin-to-creatinine ratio predict 5-year mortality and cardiovascular events in People Living with HIV independently of measured GFR. J Infect Dis 2020; 223(5): 885-92.
[http://dx.doi.org/10.1093/infdis/jiaa433] [PMID: 32691827]
[70]
Gupta SK, Kitch D, Tierney C, et al. AIDS Clinical Trials Group Study A5224s Team. Markers of renal disease and function are associated with systemic inflammation in HIV infection. HIV Med 2015; 16(10): 591-8.
[http://dx.doi.org/10.1111/hiv.12268] [PMID: 25990642]

© 2022 Bentham Science Publishers | Privacy Policy